Immunotherapy for Infectious Diseases

Fungal Infections 321
74. Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect
Immun 1995; 63:2714–2719.
75. Groll A, Renz S, Gerein V, et al. Fatal haemoptysis associated with invasive pulmonary
aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony
stimulating factor (GM-CSF). Mycoses 1992; 35:67–75.
76. Toren A, Or R, Ackerstein A, Nagler A. Invasive fungal infections in lymphoma patients
receiving immunotherapy following autologous bone marrow transplantation (ABMT).
Bone Marrow Transplant 1997; 20:67–69.
77. Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, Atkins MB. Nosocomial sepsis
associated with interleukin-2. Ann Intern Med 1990; 112:102–107.
78. Richards JM, Gilewski TA, Vogelzang NJ. Association of interleukin-2 therapy with
staphylococcal bacteremia. Cancer 1991; 67:1570–1575.
79. Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections—all
neutropenic patients are not the same. Clin Infect Dis 1994; 18:793–798.
80. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced
suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus
hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect
Immun 1993; 61:4870–4877.
81. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response
and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte
colony-stimulating factor and gamma interferon. Infect Immun 1993; 61:1185–1193.
82. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colonystimulating
factor and interferon-� on antifungal activity of human polymorphonuclear
neutrophils against pseudohyphae of different medically important Candida species.
J Leukoc Biol 1995; 57:651–656.
83. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Neutrophil oxidative burst in response
to blastoconidia and pseudohyphae of Candida albicans: augmentation by granulocyte
colony-stimulating factor and interferon-�. J Infect Dis 1992; 166:668–673.
84. Yamamoto Y, Klein TW, Friedman H, Kimura S, Yamaguchi H. Granulocyte colonystimulating
factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear
cells. FEMS Immunol Med Microbiol 1993; 1:15–22.
85. Yamamoto Y, Uchida K, Klein TW, Friedman H, Yamaguchi H. Immunomodulators and
fungal infections: use of antifungal drugs in combinations with G-CSF. Adv Exp Med Biol
1992; 319:231–242.
86. Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colonystimulating
factor administration to HIV-infected subjects augments reduced leukotriene
synthesis and anticryptococcal activity in neutrophils. J Clin Invest 1998; 102:4–663.
87. Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulocyte-macrophage colonystimulating
factor and interferon-� prevent dexamethasone-induced immunosuppression
of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol
1995; 34:63–69.
88. Yamamoto Y, Klein TW, Tomioka M, Friedman H. Differential effects of
ganulocyte/macrophage colony-stimulating factor (GM-CSF) in enhancing macrophage
resistance to Legionella pneumophila vs Candida albicans. Cell Immunol 1997;
176:75–81.
89. Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function against Candida
albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage-
CSF, and macrophage-CSF. J Immunol 1989; 143:671–677.
90. Levitz SM. Activation of human peripheral blood mononuclear cells by interleukin-2 and
granulocyte-macrophage colony stimulating factor to inhibit Cryptococcus neoformans.
Infect Immun 1991; 59:3393–3397.